147 related articles for article (PubMed ID: 25749520)
1. Leukemia inhibitory factor receptor is a novel immunomarker in distinction of well-differentiated HCC from dysplastic nodules.
Luo Q; Zhang Y; Wang N; Jin G; Jin H; Gu D; Tao X; Huo X; Ge T; Cong W; Wang C; Qin W
Oncotarget; 2015 Mar; 6(9):6989-99. PubMed ID: 25749520
[TBL] [Abstract][Full Text] [Related]
2. SUOX is a promising diagnostic and prognostic biomarker for hepatocellular carcinoma.
Jin GZ; Yu WL; Dong H; Zhou WP; Gu YJ; Yu H; Yu H; Lu XY; Xian ZH; Liu YK; Cong WM; Wu MC
J Hepatol; 2013 Sep; 59(3):510-7. PubMed ID: 23665285
[TBL] [Abstract][Full Text] [Related]
3. Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling.
Nam SW; Park JY; Ramasamy A; Shevade S; Islam A; Long PM; Park CK; Park SE; Kim SY; Lee SH; Park WS; Yoo NJ; Liu ET; Miller LD; Lee JY
Hepatology; 2005 Oct; 42(4):809-18. PubMed ID: 16175600
[TBL] [Abstract][Full Text] [Related]
4. Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis.
Nault JC; Calderaro J; Di Tommaso L; Balabaud C; Zafrani ES; Bioulac-Sage P; Roncalli M; Zucman-Rossi J
Hepatology; 2014 Dec; 60(6):1983-92. PubMed ID: 25123086
[TBL] [Abstract][Full Text] [Related]
5. [Expression and clinicopathologic significance of GPC3 and other antibodies in well-differentiated hepatocellular carcinoma].
DU JL; Wei LX; Wang YL
Zhonghua Bing Li Xue Za Zhi; 2011 Jan; 40(1):11-6. PubMed ID: 21429352
[TBL] [Abstract][Full Text] [Related]
6. The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma.
Di Tommaso L; Destro A; Seok JY; Balladore E; Terracciano L; Sangiovanni A; Iavarone M; Colombo M; Jang JJ; Yu E; Jin SY; Morenghi E; Park YN; Roncalli M
J Hepatol; 2009 Apr; 50(4):746-54. PubMed ID: 19231003
[TBL] [Abstract][Full Text] [Related]
7. LIFR functions as a metastasis suppressor in hepatocellular carcinoma by negatively regulating phosphoinositide 3-kinase/AKT pathway.
Luo Q; Wang C; Jin G; Gu D; Wang N; Song J; Jin H; Hu F; Zhang Y; Ge T; Huo X; Chu W; Shu H; Fang J; Yao M; Gu J; Cong W; Qin W
Carcinogenesis; 2015 Oct; 36(10):1201-12. PubMed ID: 26249360
[TBL] [Abstract][Full Text] [Related]
8. [Selective deposition of agrin in the microvasculature of hepatocellular carcinoma: aspects in pathogenesis and differential diagnosis].
Tátrai P
Magy Onkol; 2008 Dec; 52(4):379-83. PubMed ID: 19068466
[TBL] [Abstract][Full Text] [Related]
9. The vascular profile of regenerative and dysplastic nodules of the cirrhotic liver: implications for diagnosis and classification.
Roncalli M; Roz E; Coggi G; Di Rocco MG; Bossi P; Minola E; Gambacorta M; Borzio M
Hepatology; 1999 Nov; 30(5):1174-8. PubMed ID: 10534338
[TBL] [Abstract][Full Text] [Related]
10. EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies.
Cai MY; Tong ZT; Zheng F; Liao YJ; Wang Y; Rao HL; Chen YC; Wu QL; Liu YH; Guan XY; Lin MC; Zeng YX; Kung HF; Xie D
Gut; 2011 Jul; 60(7):967-76. PubMed ID: 21330577
[TBL] [Abstract][Full Text] [Related]
11. Leukemia inhibitory factor receptor (LIFR) is detected as a novel suppressor gene of hepatocellular carcinoma using double-combination array.
Okamura Y; Nomoto S; Kanda M; Li Q; Nishikawa Y; Sugimoto H; Kanazumi N; Takeda S; Nakao A
Cancer Lett; 2010 Mar; 289(2):170-7. PubMed ID: 19733004
[TBL] [Abstract][Full Text] [Related]
12. Agrin and CD34 immunohistochemistry for the discrimination of benign versus malignant hepatocellular lesions.
Tátrai P; Somorácz A; Batmunkh E; Schirmacher P; Kiss A; Schaff Z; Nagy P; Kovalszky I
Am J Surg Pathol; 2009 Jun; 33(6):874-85. PubMed ID: 19194276
[TBL] [Abstract][Full Text] [Related]
13. The expression of transforming growth factor-alpha in cirrhosis, dysplastic nodules, and hepatocellular carcinoma: an immunohistochemical study of 70 cases.
Yeh MM; Larson AM; Campbell JS; Fausto N; Rulyak SJ; Swanson PE
Am J Surg Pathol; 2007 May; 31(5):681-9. PubMed ID: 17460450
[TBL] [Abstract][Full Text] [Related]
14. [Dysplastic nodule of liver versus early hepatocellular carcinoma: a clinicopathologic and prognostic study].
Chen L; Tan Y; Zeng H; Hou Y; Xu J; Zhao J; Ji Y
Zhonghua Bing Li Xue Za Zhi; 2014 May; 43(5):301-6. PubMed ID: 25030861
[TBL] [Abstract][Full Text] [Related]
15. Mybl2 expression is under genetic control and contributes to determine a hepatocellular carcinoma susceptible phenotype.
Frau M; Ladu S; Calvisi DF; Simile MM; Bonelli P; Daino L; Tomasi ML; Seddaiu MA; Feo F; Pascale RM
J Hepatol; 2011 Jul; 55(1):111-9. PubMed ID: 21419759
[TBL] [Abstract][Full Text] [Related]
16. Thyroid hormone inhibits hepatocellular carcinoma progression via induction of differentiation and metabolic reprogramming.
Kowalik MA; Puliga E; Cabras L; Sulas P; Petrelli A; Perra A; Ledda-Columbano GM; Morandi A; Merlin S; Orrù C; Sanchez-Martin C; Fornari F; Gramantieri L; Parri M; Rasola A; Bellomo SE; Sebastian C; Follenzi A; Giordano S; Columbano A
J Hepatol; 2020 Jun; 72(6):1159-1169. PubMed ID: 31954205
[TBL] [Abstract][Full Text] [Related]
17. Hepatocellular dysplastic nodules.
Roncalli M; Borzio M; Di Tommaso L
Ann Ital Chir; 2008; 79(2):81-9. PubMed ID: 18727269
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic role of glypican 3 and CD34 for differentiating hepatocellular carcinoma from nonmalignant hepatocellular lesions.
Enan ET; El-Hawary AK; El-Tantawy DA; Abu-Hashim MM; Helal NM
Ann Diagn Pathol; 2013 Dec; 17(6):490-3. PubMed ID: 24012547
[TBL] [Abstract][Full Text] [Related]
19. Differentiating hepatocellular carcinoma from dysplastic nodules at gadobenate dimeglumine-enhanced hepatobiliary-phase magnetic resonance imaging.
Gatto A; De Gaetano AM; Giuga M; Ciresa M; Siciliani L; Miele L; Riccardi L; Pizzolante F; Rapaccini GL; Gasbarrini A; Giuliante F; Vecchio FM; Pompili M; Bonomo L
Abdom Imaging; 2013 Aug; 38(4):736-44. PubMed ID: 22986351
[TBL] [Abstract][Full Text] [Related]
20. Hepatic expression of the proliferative marker Ki-67 and p53 protein in HBV or HCV cirrhosis in relation to dysplastic liver cell changes and hepatocellular carcinoma.
Koskinas J; Petraki K; Kavantzas N; Rapti I; Kountouras D; Hadziyannis S
J Viral Hepat; 2005 Nov; 12(6):635-41. PubMed ID: 16255765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
